title: A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension.
abstract: BACKGROUND
  Many patients seek complementary medicine treatments like neutraceuticals for common conditions such as hypertension.
  
  
  METHODS
  We conducted a placebo-controlled prospective randomized crossover study in 10 hypertensive subjects to determine whether a single dose of a hydrolysate of bovine milk protein (designated C12 peptide; low and high dose), either alone or combined with alginic acid (low and high dose), reduced daytime blood pressure (BP), as determined by ambulatory BP monitoring.
  
  
  RESULTS
  Within the five treatment regimens a significant reduction of 9.2 +/- 3.2 mm Hg in systolic BP at h 6 compared with h 2 occurred on the higher dose of alginic acid (1754 mg) combined with C12 (P = .02). The C12 peptide with the higher dose of alginic acid also showed a significant reduction of 6.0 +/- 2.0 mm Hg in diastolic BP at h 6 compared with h 2 (P = .015).
  
  
  CONCLUSIONS
  These preliminary data are encouraging and deserve testing in a larger and longer treatment trial.
authors.affiliation: Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA. townsend@mail.med.upenn.edu
authors.forename: Raymond R
authors.initials: RR
authors.lastname: Townsend
authors.forename: Christopher B
authors.initials: CB
authors.lastname: McFadden
authors.forename: Virginia
authors.initials: V
authors.lastname: Ford
authors.forename: Jenny A
authors.initials: JA
authors.lastname: Cadée
mesh_terms: D000464:Alginates / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D002364:Caseins / Q000627:therapeutic use*; D000529:Complementary Therapies; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D020723:Glucuronic Acid / Q000627:therapeutic use; D006603:Hexuronic Acids / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D000464:Alginates; D000959:Antihypertensive Agents; D002364:Caseins; D006603:Hexuronic Acids; C475729:casein hydrolysate; D020723:Glucuronic Acid